Somatic mutations, such as NPM1, FLT3‐ITD, and TP53, enable hematopoietic stem and progenitor cells to acquire the ability of self‐renewal, which is crucial for the pathogenesis and prognosis of AML.2 The gene discussed is NPM1; the disease is acute myeloid leukemia.